, M.D., (2014-present) is an assistant clinical professor in the Department of Medical Oncology & Therapeutics at City of Hope subspecializing in gastrointestinal malignancies. His research investigates primary tumor and circulating microRNA profiles in gastroesophogeal cancer patients that may better characterize disease biology and serve as novel predictive biomarkers of drug sensitivity or resistance.
, M.D., (2015-present) is an assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope. The focus of his clinical practice and research is immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma. His research evaluates genomic biomarkers of response in patients with lymphoid malignancies who undergo adoptive cellular immunotherapy with CD19-specific chimeric-antigen receptor-modified T-cells, or CAR-T cells).
, M.D., M.S., (2015-present) is an assistant professor in the Department of Surgery at City of Hope subspecializing in hepatobiliary malignancies. Her research aims to develop salmonella-based targeting of indoleamine 2,3-dioxygenase coupled with enzymatic depletion of tumor hyaluronan as a pancreatic cancer therapy utilizing a human pancreatic xenograft model.
, M.D., M.A.S. (2014-present) is an assistant professor in the Department of Surgery at City of Hope specializing in thoracic oncology. His research focuses on his original observation of the drug triptoline as therapy for Wnt3aoverexpressing lung cancers.
, M.D., M.S. (2017-present) is an Assistant Professor in the Department of Medical Oncology and Therapeutics at City of Hope specializing in the care of older adults with breast cancer. Dr. Sedrak’s ultimate scientific goal is to improve clinical trial recruitment of older adults, a highly underrepresented group in cancer research, through design, development, and use of digital engagement interventions. The objectives of his research are to identify the facilitators and barriers of health-oriented social media-based intervention to improve informational support among older adults with breast cancer.
, M.D., Ph.D., (2014-present) is an assistant professor in the Department of Medical Oncology & Therapeutics at City of Hope specializing in breast cancer. Yuan’s interest is in developing novel therapeutics and her clinical focus is in triple negative breast cancer. Based on preclinical data from the laboratory of David Ann, Ph.D., she is testing the efficacy of pegylated arginine deaminase combined with doxorubicin in women with metastatic HER2 negative breast cancer.